compounding pharmacy glp-1 fda enforcement news today and Novo Nordisk Warn of Telehealth Take Down – What's Next? FDA issued 25 warning letters

Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases

Is there any way to remove the abnormal lipedema fat without surgery

References Clemmitt, R

Peptide Therapy and Menopause or Andropause: Addressing the Overlap Adults over 60 often arrive at peptide therapy in the context of established hormonal decline menopause in women, andropause in men